What’s the Half-Life of CJC-1295? (With vs Without DAC)

What's the Half-Life of CJC-1295? (With vs Without DAC)

The most important thing to understand about what's the half-life of CJC-1295 is that there are actually two different compounds sharing the same base name. And their pharmacokinetics couldn't be more different. CJC-1295 with DAC (Drug Affinity Complex) has a half-life of approximately 6–8 days, allowing weekly or twice-weekly dosing. The modified version. Often called 'CJC-1295 without DAC' or simply 'Modified GRF(1-29)'. Has a half-life of less than 30 minutes, requiring multiple daily administrations for sustained GH pulse elevation. The DAC molecule binds the peptide to serum albumin, extending circulation time by preventing enzymatic degradation that would otherwise occur within minutes.

Our team has worked with researchers across metabolic health, performance optimization, and regenerative medicine protocols for years. The confusion around CJC-1295 half-life is one of the most common sourcing errors we see. Labs ordering the wrong variant because they assumed 'CJC-1295' meant a single compound with a single dosing schedule.

What's the half-life of CJC-1295?

CJC-1295 with DAC has a terminal half-life of approximately 6–8 days, meaning it takes roughly one week for plasma concentrations to drop by 50% after a single injection. The non-DAC version (Modified GRF 1-29) has a half-life of under 30 minutes due to rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4). This difference fundamentally changes dosing frequency: the DAC version sustains elevated growth hormone levels across multiple days, while the non-DAC variant produces acute GH pulses that dissipate within hours.

Here's what most guides overlook: the extended half-life of CJC-1295 with DAC wasn't the primary design goal. It was a mechanism to prevent the peptide's near-instant degradation by DPP-4 enzymes in plasma. Growth hormone-releasing hormone (GHRH) analogs like native GHRH(1-44) or unmodified GRF(1-29) are cleaved at the Ala2 position within minutes of entering circulation. The Drug Affinity Complex. Four lysine molecules covalently bonded to the peptide's structure. Binds to serum albumin and physically shields the cleavage site from DPP-4 access. What you're dosing isn't just a longer-acting peptide; it's a peptide-albumin conjugate that circulates as a bound complex.

CJC-1295 Variants: DAC vs Non-DAC Pharmacokinetics

The half-life difference between CJC-1295 variants stems from one structural modification: the presence or absence of the Drug Affinity Complex. CJC-1295 with DAC is tetrasubstituted GHRH(1-29) with four maleimidoproprionic acid-lysine groups attached at positions 8, 15, 21, and 27. These lysine arms bind covalently to serum albumin. The most abundant plasma protein. Creating a conjugate that cannot be filtered through the kidneys or degraded by circulating proteases. Modified GRF(1-29) (the non-DAC version) contains amino acid substitutions at positions 2, 8, 15, and 27 to resist DPP-4 cleavage, but without albumin binding, it still clears from plasma within 30 minutes.

A 2006 phase I study published in the Journal of Clinical Endocrinology & Metabolism measured CJC-1295 with DAC concentrations over 28 days following a single subcutaneous injection. Peak plasma levels occurred at 24–72 hours post-injection, with detectable concentrations persisting beyond 14 days. Growth hormone secretion remained elevated for 6+ days, returning to baseline only after the peptide fully dissociated from albumin. The same study confirmed DPP-4 resistance through enzymatic assays. Albumin-bound CJC-1295 showed no measurable degradation after 24-hour incubation with DPP-4, while unbound GHRH(1-29) was completely cleaved within 10 minutes.

What's the half-life of CJC-1295 without DAC in practical terms? Plasma half-life is under 30 minutes, but biological half-life. The duration of elevated GH secretion. Extends to approximately 2–3 hours due to receptor binding at the pituitary. This is why Modified GRF(1-29) is typically dosed 2–3 times daily, timed to coincide with natural GH pulse windows (upon waking, post-training, before sleep). Researchers aiming to replicate physiological GH pulsatility prefer the non-DAC variant precisely because it doesn't create sustained supraphysiological elevation across multiple days.

Dosing Implications of CJC-1295 Half-Life

What's the half-life of CJC-1295 mean for protocol design? With the DAC version, steady-state plasma concentrations are reached after 3–4 injections at weekly intervals. Roughly 21–28 days into a protocol. This creates continuous GH elevation rather than pulsatile release, which some research suggests may desensitize GH receptors or suppress endogenous pulsatility over time. The non-DAC variant mimics physiological GH secretion: acute pulses lasting 2–3 hours, followed by return to baseline before the next dose. Protocols using Modified GRF(1-29) typically dose 100–200 mcg per administration, 2–3 times daily. CJC-1295 with DAC is dosed at 1–2 mg per week due to accumulation across the dosing interval.

Storage requirements differ based on half-life dynamics. CJC-1295 with DAC maintains activity for 28+ days when refrigerated at 2–8°C after reconstitution, because the albumin-bound complex is inherently more stable than free peptide. Modified GRF(1-29) degrades more rapidly once in solution. Reconstituted vials should be used within 14–21 days even under refrigeration. Both peptides are supplied as lyophilized powder and must be stored at −20°C before mixing with bacteriostatic water. Temperature excursions above 25°C for more than 48 hours can denature the tertiary structure of the peptide chain, rendering it biologically inactive regardless of half-life.

One critical dosing error we see frequently: researchers attempting to 'bridge' between DAC and non-DAC variants by adjusting dose alone. A 1 mg weekly dose of CJC-1295 with DAC does not produce the same GH response pattern as 200 mcg of Modified GRF(1-29) dosed daily. The former creates sustained elevation; the latter creates discrete pulses. Total GH secretion over a week may be comparable, but the temporal distribution. Continuous vs pulsatile. Affects downstream IGF-1 production, receptor sensitivity, and metabolic outcomes differently. These are not interchangeable compounds at adjusted doses; they're distinct pharmacological tools.

CJC-1295 Half-Life: DAC vs Non-DAC Comparison

The table below compares the two CJC-1295 variants across key pharmacokinetic and practical parameters. Understanding these differences is essential for selecting the appropriate peptide for specific research applications.

Plasma Half-Life

6–8 days

<30 minutes

DAC extends circulation by >200× through albumin binding

Biological Half-Life (GH Elevation)

6+ days continuous

2–3 hours per dose

Non-DAC mimics natural pulsatile GH release

Typical Dosing Frequency

Once or twice weekly

2–3 times daily

DAC reduces administration burden but removes pulsatility

Dose Per Administration

1–2 mg per injection

100–200 mcg per injection

Weekly DAC dose ~7× higher due to sustained release

Time to Steady State

21–28 days (3–4 injections)

Immediate (no accumulation)

DAC requires loading period; non-DAC reaches effect within hours

Receptor Desensitization Risk

Moderate to high (continuous elevation)

Low (pulsatile matches physiology)

Prolonged GH elevation may reduce receptor sensitivity over time

Reconstituted Stability (2–8°C)

28+ days

14–21 days

Albumin binding stabilizes DAC version in solution

Primary Research Use Case

Sustained anabolic stimulus, convenience dosing

Mimicking natural GH pulsatility, performance timing

Choose based on desired GH secretion pattern, not just convenience

Key Takeaways

CJC-1295 with DAC has a half-life of approximately 6–8 days due to albumin binding via lysine substitutions at four positions on the peptide backbone.

Modified GRF(1-29) (CJC-1295 without DAC) has a plasma half-life under 30 minutes but produces GH pulses lasting 2–3 hours per dose.

The Drug Affinity Complex prevents DPP-4 enzymatic degradation. Without it, GHRH analogs are cleaved at the Ala2 position within minutes.

DAC-conjugated CJC-1295 creates continuous GH elevation across multiple days, while the non-DAC variant mimics physiological pulsatile secretion.

Weekly dosing (1–2 mg) is standard for CJC-1295 with DAC; Modified GRF(1-29) requires 2–3 daily administrations at 100–200 mcg per dose.

Steady-state plasma levels with the DAC version are reached after 3–4 weekly injections. Approximately 21–28 days into a protocol.

Reconstituted CJC-1295 with DAC remains stable for 28+ days at 2–8°C; the non-DAC variant should be used within 14–21 days after mixing.

What If: CJC-1295 Half-Life Scenarios

What If I Miss a Weekly CJC-1295 with DAC Injection?

Administer the missed dose as soon as you remember if fewer than 4 days have passed since your scheduled injection. If more than 4 days have elapsed, skip the missed dose and resume your regular weekly schedule. Do not double-dose to 'catch up'. CJC-1295 with DAC accumulates over multiple injections to reach steady state, and doubling a dose creates a concentration spike that may trigger side effects (flushing, water retention, transient insulin resistance) without proportional benefit. Missing a single dose extends the time to steady state by one additional week but doesn't reset your protocol entirely.

What If I Accidentally Stored Reconstituted CJC-1295 at Room Temperature Overnight?

If reconstituted CJC-1295 with DAC was left at room temperature (20–25°C) for fewer than 24 hours, refrigerate it immediately and continue use. Short-term temperature excursions cause minimal degradation in albumin-bound peptides. Beyond 24 hours or if the vial reached temperatures above 30°C, discard it. Peptide structure begins denaturing above 25°C, and there's no reliable way to test potency at home. For Modified GRF(1-29), the threshold is stricter: discard if left unrefrigerated for more than 12 hours, as the unbound peptide degrades faster than the DAC version.

What If I Want to Switch from CJC-1295 with DAC to Modified GRF(1-29)?

Allow at least 14 days after your final CJC-1295 with DAC injection before starting Modified GRF(1-29). The DAC version's extended half-life means circulating levels remain elevated for 2+ weeks after stopping. Starting the non-DAC variant immediately creates overlapping GH stimulation that compounds rather than replaces. During the washout period, endogenous GH secretion gradually returns to baseline. Once you begin Modified GRF(1-29), start at 100 mcg per dose, 2–3 times daily, rather than attempting to 'bridge' by splitting your previous weekly DAC dose across daily administrations.

What If I Experience Water Retention on CJC-1295 with DAC?

Water retention and mild edema are common with sustained GH elevation because growth hormone promotes sodium retention in the kidneys and increases aldosterone secretion. This typically resolves within 2–3 weeks as the body adapts to elevated GH levels. If symptoms persist beyond 4 weeks or worsen (tight rings, facial puffiness, joint stiffness), reduce your dose by 25–30% for the next injection and reassess. Switching to Modified GRF(1-29) eliminates continuous elevation and often resolves retention entirely. Pulsatile GH release doesn't trigger the same aldosterone response as sustained supraphysiological levels.

The Unvarnished Truth About CJC-1295 Half-Life

Here's the honest answer: most researchers using 'CJC-1295' have no idea whether they're dosing the DAC version or Modified GRF(1-29). And many suppliers deliberately obscure the distinction to sell whichever variant they have in stock. If your product label says 'CJC-1295' without specifying 'with DAC' or 'no DAC', you're purchasing blind. The two compounds have completely different half-lives, dosing schedules, and GH secretion patterns. They are not interchangeable. What's the half-life of CJC-1295 becomes a meaningless question if you don't know which structural variant you received. Legitimate suppliers state the exact peptide sequence and specify DAC presence or absence on every vial. If yours doesn't, you're not working with a research-grade source.

The extended half-life of CJC-1295 with DAC was engineered for convenience, not for superior results. Continuous GH elevation across 6–8 days sounds advantageous until you consider that physiological GH secretion is pulsatile for a reason. Sustained elevation desensitizes receptors, suppresses endogenous secretion, and alters metabolic signaling in ways we're still mapping. Modified GRF(1-29) mimics natural physiology. The DAC version overrides it. Neither is 'better'. They serve different research objectives. If your goal is to replicate natural GH dynamics, the short half-life variant is the correct choice. If you're testing sustained anabolic stimulus or need simplified dosing in a large cohort, DAC makes sense. But treating them as equivalent compounds at adjusted doses is a fundamental protocol error.

CJC-1295 Mechanism: Why Half-Life Matters for GH Pulsatility

Growth hormone is released in pulses throughout the day. Not as a continuous baseline secretion. The pituitary somatotrophs respond to GHRH (growth hormone-releasing hormone) signals from the hypothalamus by releasing GH in discrete bursts lasting 1–3 hours, with the largest pulses occurring during deep sleep and immediately post-exercise. CJC-1295, whether with or without DAC, is a synthetic GHRH analog that binds to GHRH receptors on somatotrophs and triggers GH release. What's the half-life of CJC-1295 determines whether that receptor stimulation is brief (mimicking a natural pulse) or sustained (creating continuous non-physiological elevation).

The albumin-binding mechanism of CJC-1295 with DAC means the peptide remains attached to circulating albumin for days, slowly dissociating to bind GHRH receptors over time. This creates a 'depot effect'. Rather than a single intense pulse, you get moderate continuous stimulation across the entire dosing interval. Receptor occupancy studies show that GHRH receptors remain partially saturated for 5–7 days after a single DAC injection, preventing the sharp on-off pulsatility that characterizes natural GH secretion. Modified GRF(1-29), with its sub-30-minute plasma half-life, binds receptors acutely, triggers a GH pulse, and clears before the next scheduled dose. Replicating the body's endogenous rhythm.

Our experience working with researchers across performance and longevity protocols consistently shows one pattern: those prioritizing convenience gravitate toward CJC-1295 with DAC; those prioritizing physiological mimicry choose Modified GRF(1-29). The former reduces injection frequency to once or twice weekly. The latter requires 2–3 daily administrations but preserves the pulsatile GH secretion pattern that downstream metabolic pathways evolved to respond to. There's no universal 'right' answer. The correct peptide depends on whether your research question values convenience or biomimicry.

When sourcing CJC-1295 for research, half-life verification should be part of your quality assessment. Request third-party HPLC (high-performance liquid chromatography) analysis showing peptide purity above 98% and confirming the presence or absence of DAC substitution. Real Peptides provides batch-specific purity documentation and clearly labels DAC status on every product. The kind of transparency that separates research-grade suppliers from ambiguous sources. Half-life isn't just a dosing consideration; it's a fundamental structural property that defines how the peptide interacts with your research model. Treating it as an afterthought invites protocol errors that compromise data integrity from day one.

The distinction between CJC-1295 with DAC and Modified GRF(1-29) isn't academic nuance. It's the difference between replicating natural physiology and deliberately overriding it. If the peptide you're using doesn't specify which variant you received, you're introducing an uncontrolled variable into every protocol that uses it.

Frequently Asked Questions

CJC-1295 with DAC has a terminal half-life of approximately 6–8 days, allowing once or twice-weekly dosing. The Drug Affinity Complex binds the peptide to serum albumin, preventing enzymatic degradation and extending circulation time by more than 200-fold compared to unmodified GHRH analogs. Plasma concentrations remain elevated for 10–14 days after a single injection, with detectable GH elevation persisting for 6+ days.

Modified GRF(1-29) (CJC-1295 without DAC) has a plasma half-life of less than 30 minutes due to rapid clearance and enzymatic degradation. However, the biological half-life — the duration of elevated growth hormone secretion — extends to approximately 2–3 hours per dose because the peptide remains bound to pituitary GHRH receptors during that window. This is why it requires 2–3 daily administrations rather than weekly dosing.

Yes, some protocols use twice-weekly dosing (e.g., every 3–4 days) to maintain more consistent plasma levels, though once-weekly administration at 1–2 mg is the most common approach. Because the half-life is 6–8 days, steady-state concentrations are reached after 3–4 injections regardless of frequency. Dosing more frequently than twice weekly provides minimal additional benefit and increases the risk of receptor desensitization from continuous GH elevation.

If you miss a scheduled dose by fewer than 4 days, administer it as soon as you remember and continue your regular weekly schedule. If more than 4 days have passed, skip the missed dose entirely and resume on your next scheduled date — do not double-dose. Missing a single injection delays steady-state by approximately one week but doesn’t reset your protocol. CJC-1295 with DAC accumulates over multiple doses, so concentration spikes from double-dosing can trigger water retention and insulin resistance.

Neither variant has inherently greater safety — the risk profile depends on the GH secretion pattern each produces. CJC-1295 with DAC creates sustained GH elevation over multiple days, which may suppress endogenous pulsatility and increase risk of receptor desensitization. Modified GRF(1-29) produces acute pulses that mimic natural physiology, reducing the likelihood of receptor downregulation. Both are well-tolerated in research settings when dosed appropriately, but continuous vs pulsatile GH elevation has different long-term metabolic implications.

Legitimate research-grade suppliers specify ‘with DAC’ or ‘Modified GRF(1-29)’ on the product label and provide third-party HPLC analysis confirming peptide structure. If the label only says ‘CJC-1295’ without clarification, you cannot determine which variant you received without independent testing. The two compounds have different molecular weights (CJC-1295 with DAC is significantly heavier due to lysine substitutions), so mass spectrometry or HPLC can definitively identify DAC presence.

Sustained growth hormone elevation increases sodium reabsorption in the kidneys and stimulates aldosterone secretion, both of which promote fluid retention. This is a dose-dependent effect — higher doses or more frequent administration compound the response. Water retention typically resolves within 2–4 weeks as the body adapts to elevated GH levels. If symptoms persist beyond 4 weeks, reducing dose by 25–30% or switching to Modified GRF(1-29) (which produces pulsatile rather than continuous elevation) usually resolves the issue.

Current research has explored PEGylation (attaching polyethylene glycol chains) and alternative albumin-binding motifs to extend half-life beyond 8 days, but these remain experimental. The DAC modification already achieves near-maximal half-life extension through albumin binding — further extensions would require preventing albumin dissociation entirely, which may increase immunogenicity or reduce receptor binding efficiency. For research applications requiring even longer action, sustained-release depot formulations are under investigation but not commercially available.

The intrinsic half-life of CJC-1295 with DAC (6–8 days) does not change with repeated administration, but steady-state plasma concentrations increase over the first 3–4 injections as each dose overlaps with residual circulating peptide from prior doses. After reaching steady state (approximately 21–28 days), plasma levels stabilize and the effective half-life remains constant. Modified GRF(1-29) does not accumulate because it clears completely between doses, so its half-life remains under 30 minutes regardless of protocol duration.

CJC-1295 with DAC is typically 30–50% more expensive per milligram than Modified GRF(1-29) due to the additional synthesis steps required to attach the Drug Affinity Complex. However, because weekly dosing (1–2 mg) of the DAC version covers the same timeframe as 14–21 daily doses (100–200 mcg each) of Modified GRF(1-29), total cost per week is often comparable. The primary cost difference is in administration convenience — fewer injections with DAC vs multiple daily doses with the non-DAC variant.

Yes, CJC-1295 with DAC is frequently stacked with growth hormone secretagogues like ipamorelin or GHRP-2 to amplify GH release through complementary mechanisms — CJC-1295 stimulates GHRH receptors while GHRPs activate ghrelin receptors. This combination produces synergistic GH elevation greater than either peptide alone. However, stacking continuous GH stimulation (DAC) with additional secretagogues increases the risk of receptor desensitization over time, so protocols typically cycle on/off every 8–12 weeks to preserve endogenous pulsatility.